We are live on ! Find out more
VAXX

Vaxxinity, Inc. Class A Common Stock

Delisted

VAXX was delisted on the 8th of May, 2024.

29 hedge funds and large institutions have $48.5M invested in Vaxxinity, Inc. Class A Common Stock in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more capital invested

Capital invested by funds: $38.2M → $48.5M (+$10.3M)

0% more funds holding

Funds holding: 2929 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

67% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 9

Holders
29
Holders Change
Holders Change %
0%
% of All Funds
0.5%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
8
Increased
3
Reduced
9
Closed
8
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Osaic Holdings
26
Osaic Holdings
Arizona
$7K
GWS
27
Glassman Wealth Services
Virginia
$5K
BNP Paribas Financial Markets
28
BNP Paribas Financial Markets
France
$182 +$192 +92 New
ECM
29
Element Capital Management
New York
-$592K -376,886 Closed
Squarepoint
30
Squarepoint
New York
-$24K -15,417 Closed
DTL
31
Dynamic Technology Lab
Singapore
-$21K -13,582 Closed
VF
32
Virtu Financial
New York
-$20K -12,760 Closed
FIA
33
FNY Investment Advisers
New York
-$17K -11,000 Closed
Citigroup
34
Citigroup
New York
-$2K -1,447 Closed
TRCT
35
Tower Research Capital (TRC)
New York
-$1K -1,193 Closed
Royal Bank of Canada
36
Royal Bank of Canada
Ontario, Canada
-$2K -1,000 Closed
Wells Fargo
37
Wells Fargo
California
+$495 +238 New

VAXX Hedge Fund Activity: Q3 2022 in Review

29 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Vaxxinity, Inc. Class A Common Stock (VAXX) for Q3 2022, worth a combined $48.5M — up 27% from $38.2M a quarter earlier.

Fund positioning in VAXX was balanced in Q3 2022: 8 funds opened new positions, 8 closed out, 3 added to existing stakes and 9 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.42M. The largest seller was Marshall Wace, cutting an estimated $920K.

  • 29 institutional investors held Vaxxinity, Inc. Class A Common Stock (VAXX) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $48.5M of Vaxxinity, Inc. Class A Common Stock stock for Q3 2022, up 27% quarter-over-quarter.
  • 8 funds opened new Vaxxinity, Inc. Class A Common Stock positions in Q3 2022 and 8 closed out, a net change of 0 holders.
  • The largest Vaxxinity, Inc. Class A Common Stock buyer in Q3 2022 was Vanguard Group, an estimated $1.42M added.
  • The largest Vaxxinity, Inc. Class A Common Stock seller in Q3 2022 was Marshall Wace, an estimated $920K sold.

Based on aggregated 13F filings for Q3 2022.